News | November 12, 2008

Medtronic Completes Enrollment Ahead of Schedule in Key Endeavor Resolute DES Trial

November 13, 2008 - Medtronic Inc. said yesterday its enrollment in the 2,300-patient RESOLUTE All-Comers (R-AC) clinical study was completed in just six months, two months ahead of schedule.

The randomized trial compares the safety and efficacy of Medtronic's Endeavor Resolute drug-eluting stent (DES) with Abbott Laboratories' Xience DES.

"The pace at which this trial enrolled is testimony to the intense focus and collaborative spirit of an excellent team of investigators," said Professor Patrick Serruys of Erasmus Medical Center's Thoraxcenter in Rotterdam, the Netherlands, on behalf of his co-principal investigators, Professor Sigmund Silber of the Heart Catheterization Centre in Munich, Germany, and Professor Stephan Windecker of University Hospital Bern in Switzerland. "We are all committed to rigorous follow-up to ensure that our patients' participation in the study adds considerably to the deepening understanding of how the Resolute and Xience drug-eluting stents perform in real-world clinical practice."

Launched outside the U.S. in October 2007, the Endeavor Resolute DES expands Medtronic's international stent portfolio for patients with coronary artery disease. The Endeavor Resolute DES received the CE Mark in October 2007 and is commercially available in more than 100 countries worldwide. In the U.S. its use is limited to investigational clinical trials.

The Endeavor Resolute DES features the highly-biocompatible BioLinx polymer, the first polymer designed specifically for use on a DES. The BioLinx polymer is designed to extend the duration of drug exposure in the vessel - an elution profile of potential relevance to patients that physicians consider to be at high risk of needing a repeat procedure - without trading off polymer biocompatibility, the company said.

R-AC is one part of the comprehensive RESOLUTE clinical program, which will enroll a total of more than 6,000 patients worldwide across a series of single-arm and randomized controlled trials. Enrollment in both RESOLUTE U.S. (R-U.S.) and RESOLUTE International (R-Int) began in August. R-U.S. (n=1,399) is a prospective, multicenter, controlled trial; R-Int (n=2,200) is a prospective, multicenter registry.

The RESOLUTE clinical program is a collaborative effort involving hundreds of medical centers in more than 25 countries across Europe, Asia, the Pacific Rim, the Middle East, Africa, Latin America and North America.

R-AC symmetrically randomized 2,300 unselected patients to the Endeavor Resolute DES or the Xience DES stent at 17 prominent medical centers in Europe and Israel. The primary endpoint for R"‘AC is target lesion failure, a composite of cardiac death, myocardial infarction and target lesion revascularization, within 12 months.

For more information: www.medtronic.com

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init